Center-Authored Papers

Filters: Keyword is Taxoids  [Clear All Filters]
A
Adelstein DJ, Moon J, Hanna E, Giri SPG, Mills GM, Wolf GT, Urba SG.  2010.  Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II tria. Head & neck. 32(2):221-8. Abstract
C
Carlson JJ, Garrison LP, Ramsey SD, Veenstra DL.  2009.  The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 12(1):20-7. Abstract
E
Eaton KD, Martins RG.  2010.  Maintenance chemotherapy in non-small cell lung cancer.. Journal of the National Comprehensive Cancer Network : JNCCN. 8(7):815-21. Abstract
G
Geng H, Rademacher BL, Pittsenbarger J, Huang C-Y, Harvey CT, Lafortune MC, Myrthue A, Garzotto M, Nelson PS, Beer TM et al..  2010.  ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21.. Cancer research. 70(8):3239-48. Abstract
Girard E, Ditzler S, Lee D, Richards A, Yagle K, Park J, Eslamy H, Bobilev D, Vrignaud P, Olson J.  2015.  Efficacy of cabazitaxel in mouse models of pediatric brain tumors.. Neuro-oncology. 17(1):107-15. Abstract
H
Hussain M, Goldman B, Tangen CM, Higano CS, Petrylak DP, Wilding G, Akdas AM, Small EJ, Donnelly BJ, Sundram SK et al..  2009.  Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(15):2450-6. Abstract
K
Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung YC, Lau DHM, Crowley J, Gandara DR.  2008.  Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(15):2450-6. Abstract
L
Lyman GH, Dale DC, Tomita D, Whittaker S, Crawford J.  2013.  A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting.. Breast cancer research and treatment. 139(3):863-72. Abstract
M
Moinpour CM, Donaldson GW, Nakamura Y.  2009.  Chemotherapeutic impact on pain and global health-related quality of life in hormone-refractory prostate cancer: Dynamically Modified Outcomes (DYNAMO) analysis of a randomized controlled trial.. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 18(2):147-55. Abstract
Q
Qian DZ, Rademacher BLS, Pittsenbarger J, Huang C-Y, Myrthue A, Higano CS, Garzotto M, Nelson PS, Beer TM.  2010.  CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity.. The Prostate. 70(4):433-42. Abstract
S
Swisher EM, Gonzalez RM, Taniguchi T, Garcia RL, Walsh T, Goff BA, Welcsh P.  2009.  Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas.. Molecular cancer. 8:48. Abstract
U
Unger JM, Hershman DL, Martin D, Etzioni RB, Barlow WE, LeBlanc M, Ramsey SD.  2015.  The diffusion of docetaxel in patients with metastatic prostate cancer.. Journal of the National Cancer Institute. 107(2) Abstract
W
Weycker D, Edelsberg J, Kartashov A, Barron R, Lyman G.  2012.  Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer.. Chemotherapy. 58(1):8-18. Abstract
Y
Yu EY, Muzi M, Hackenbracht JA, Rezvani BB, Link JM, Montgomery RB, Higano CS, Eary JF, Mankoff DA.  2011.  C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy.. Clinical nuclear medicine. 36(3):192-8. Abstract